To identify the cells expressing high levels of p16Ink4a, and to characterize the action of these cells on the tumor ecosystem, we combined single-cell and bulk RNA sequencing (RNAseq) analysis at early and late time points after the senolytic treatment. The gene discussed is CDKN2A; the disease is neoplasm.